ALGORAE PHARMACEUTICALS LIMITED — AGM Information 2014

Nov 17, 2014

==> picture [241 x 140] intentionally omitted <==

CEO presentation to the AGM Dr Ken Taylor 18 November 2014 http://www.lctglobal.com

Safe Harbour Statement

==> picture [113 x 52] intentionally omitted <==

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forwardlooking statements contained in this document as a result of new information, future events or developments or otherwise.

Milestones achieved in 2014

==> picture [113 x 52] intentionally omitted <==

• Resumed NTCELL clinical trial

• Regained 100% ownership of NTCELL

• Finalised QA/CT SOPs/GCP

• Completed recruitment of all four patients for Parkinson’s disease trial

• • Scientific advisors appointed: Roger Barker (Cambridge, UK), Richard Faull (Auckland, NZ), Anne Young (Harvard, US)

• Collaboration agreement with Centre for Brain Research, Auckland

• Raised A$3M through high quality investors from New Zealand

• Secured OPF financing of DOL joint venture

• Streamlined IP portfolio and patent strategies

• Initiated grant applications for non-dilutive financing

NTCELL Phase I/IIa clinical trial team

Living Cell Technologies Auckland Clinical Site Ken Taylor, PhD Barry Snow, MBChB, FRACP LCT CEO Principal Investigator, Neurologist Kathleen Durbin, PhD Mark Simpson, Clinical and Regulatory Manager Investigator, Neurologist Jenny Han, BPharm Hons Ari Bok, MBChB, FRACS Clinical Trials Officer Neurosurgeon Michelle Lockhart, PhD Lorraine Macdonald, RGON, Head of Quality Assurance BHSc (Nsg) Study Nurse DSMB Prof Tim Anderson (Neurologist, Chair); Dr Rod Ellis-Pegler (ID); Dr Andrew Hughes (Neurologist)

==> picture [113 x 52] intentionally omitted <==

Scientific Advisors Anne B Young, MD Professor of Neurology, Harvard Medical School, Boston, USA Roger Barker, MD Professor of Clinical Neurosciences and Deputy Director, John van Geest Centre for Brain Research, University of Cambridge, UK Richard Faull, MBChB, PhD Professor of Anatomy and Director, Centre for Brain Research, University of Auckland, NZ

Clinical trial timeline: NTCELL for Parkinson’s disease

==> picture [113 x 52] intentionally omitted <==

==> picture [652 x 198] intentionally omitted <==

----- Start of picture text -----

Q3 2013 Q4 2014 Q1 2014 Q2 2014 Q3 2014 Q4 2015 Q1 2015 Q2 2015 Q3 2015 Q4
Clinical Trial
Patient #1 Patient #1
Patient #2 Patient #2
Patient #3 Patient #3
Patient #4 Patient #4
6 months data from all patients expected
----- End of picture text -----

==> picture [113 x 52] intentionally omitted <==

==> picture [720 x 201] intentionally omitted <==

What is NTCELL? Jackie Lee, PhD Head of Research & Development

Brain: ventricles, CSF and choroid plexus

==> picture [113 x 52] intentionally omitted <==

Side view

Front view

==> picture [205 x 159] intentionally omitted <==

Choroid Plexus:

• Secretes cerebrospinal fluid (CSF)

• Provides neurotrophic factors

• Provides neuroprotective factors

• Removes toxin (drugs, metals, etc.)

• • Clears waste products

NTCELL: Encapsulated neonatal porcine choroid plexus

==> picture [486 x 268] intentionally omitted <==

==> picture [205 x 158] intentionally omitted <==

==> picture [79 x 162] intentionally omitted <==

Nigrostriatal dopaminergic activation: in healthy vs. Parkinson’s brains

==> picture [113 x 52] intentionally omitted <==

==> picture [76 x 50] intentionally omitted <==

Healthy brain

Parkinson’s disease

+ NTCELL

==> picture [232 x 165] intentionally omitted <==

==> picture [232 x 162] intentionally omitted <==

==> picture [231 x 164] intentionally omitted <==

NTCELL implantation into the putamen of Parkinson’s patients

==> picture [76 x 50] intentionally omitted <==

==> picture [76 x 50] intentionally omitted <==

Side view

Front view

==> picture [113 x 52] intentionally omitted <==

==> picture [44 x 324] intentionally omitted <==

==> picture [113 x 52] intentionally omitted <==

==> picture [720 x 201] intentionally omitted <==

Pipeline projects: collaboration with Centre for Brain Research

Prof Richard Faull Director

Centre for Brain Research

==> picture [113 x 52] intentionally omitted <==

• 59 different research groups

• Clinical researchers

• Cognitive neuroscientists

==> picture [256 x 81] intentionally omitted <==

• Molecular and cellular neuroscience

==> picture [205 x 271] intentionally omitted <==

• Sensory and motor neuroscience

• Imaging specialists

• More than 350 researchers

• Neurological Foundation Human Brain Bank

• • Hugh Green Trust Biobank

• • Brain Recovery Clinic (stroke and dementia)

• • NeuroDiscovery platforms

A Foundation of International Expertise and Collaboration

==> picture [113 x 52] intentionally omitted <==

==> picture [714 x 392] intentionally omitted <==

==> picture [157 x 50] intentionally omitted <==

Opportunity: Neurodegenerative Disorders

==> picture [113 x 52] intentionally omitted <==

• Parkinson’s disease (PD)

• Estimated 7-10 million people worldwide are living with PD

• – Incidence increases with age; 4% of Parkinson’s patients are diagnosed before 50 years

• Huntington’s disease (HD)

• Up to 490,000 people worldwide may be affected by HD

• – Up to 1.7 million may have a 50% risk of developing HD

• • Alzheimer’s disease (AD)

• Estimated at least 26 million people worldwide have AD

• – Incidence increases with age; high care-giver burden

• Research opportunities

• Determine methods to delay the onset and minimise effects of neurodegeneration

• Identify mechanisms of neuroplasticity and enhance recovery

• – Test research results in research clinics and roll out to community

==> picture [157 x 50] intentionally omitted <==

==> picture [113 x 52] intentionally omitted <==

==> picture [720 x 201] intentionally omitted <==

Increasing shareholder value Ken Taylor, PhD Chief executive

Movement Disorder Society of Australia

==> picture [113 x 52] intentionally omitted <==

2014 conference, 18-19 August 2014 Advanced therapies for Parkinson’s disease: • Deep brain stimulation • Duo-dopa (jejenum implant) • Apomorphine brain implant Conclusions: Advanced therapies accepted as the future for Parkinson’s treatment, but expensive (>USD100,000); short-term improvement; on-going maintenance; early intervention provides best responses.

==> picture [225 x 158] intentionally omitted <==

==> picture [190 x 153] intentionally omitted <==

Presentation of Phase I/IIa clinical trial results

==> picture [113 x 52] intentionally omitted <==

The dates below are given as a guide only

• 8 January 2015: Abstract submitted

• 30 May 2015: Scientific advisors (Prof Roger Barker, Prof Richard Faull and Prof Anne Young) review results

• 14-18 June 2015: Barry Snow to present results of trial at the 19[th] International Congress of Parkinson’s Disease and Movement Disorders

==> picture [251 x 178] intentionally omitted <==